Kim DDH, Novitzky Basso I, Kim TS, Yi SY, Kim KH, Murphy T, et al. The 17-gene stemness score associates with relapse risk and long-term outcomes following allogeneic haematopoietic cell transplantation in acute myeloid leukaemia. EJHaem. 2022;3:873–84.
Google ScholarÂ
Thoms JAI, Beck D, Pimanda JE. Transcriptional networks in acute myeloid leukemia. Genes Chromosomes Cancer. 2019;58:859–74.
Google ScholarÂ
Goyama S, Yamamoto G, Shimabe M, Sato T, Ichikawa M, Ogawa S, et al. Evi-1 is a critical regulator for hematopoietic stem cells and transformed leukemic cells. Cell Stem Cell. 2008;3:207–20.
Google ScholarÂ
Kataoka K, Sato T, Yoshimi A, Goyama S, Tsuruta T, Kobayashi H, et al. Evi1 is essential for hematopoietic stem cell self-renewal, and its expression marks hematopoietic cells with long-term multilineage repopulating activity. J Exp Med. 2011;208:2403–16.
Google ScholarÂ
Wu X, Wang H, Deng J, Zheng X, Ling Y, Gong Y. Prognostic significance of the EVI1 gene expression in patients with acute myeloid leukemia: a meta-analysis. Ann Hematol. 2019;98:2485–96.
Google ScholarÂ
Laricchia-Robbio L, Nucifora G. Significant increase of self-renewal in hematopoietic cells after forced expression of EVI1. Blood Cells Mol Dis. 2008;40:141–7.
Google ScholarÂ
Kustikova OS, Schwarzer A, Stahlhut M, Brugman MH, Neumann T, Yang M, et al. Activation of Evi1 inhibits cell cycle progression and differentiation of hematopoietic progenitor cells. Leukemia. 2013;27:1127–38.
Google ScholarÂ
Buonamici S, Li D, Chi Y, Zhao R, Wang X, Brace L, et al. EVI1 induces myelodysplastic syndrome in mice. J Clin Investig. 2004;114:713–9.
Google ScholarÂ
Yoshimi A, Goyama S, Watanabe-Okochi N, Yoshiki Y, Nannya Y, Nitta E, et al. Evi1 represses PTEN expression and activates PI3K/AKT/mTOR via interactions with polycomb proteins. Blood. 2011;117:3617–28.
Google ScholarÂ
Kurokawa M, Mitani K, Irie K, Matsuyama T, Takahashi T, Chiba S, et al. The oncoprotein Evi-1 represses TGF-beta signalling by inhibiting Smad3. Nature. 1998;394:92–6.
Google ScholarÂ
Xu X, Woo CH, Steere RR, Lee BC, Huang Y, Wu J, et al. EVI1 acts as an inducible negative-feedback regulator of NF-kappaB by inhibiting p65 acetylation. J Immunol. 2012;188:6371–80.
Google ScholarÂ
Masamoto Y, Chiba A, Mizuno H, Hino T, Hayashida H, Sato T, et al. EVI1 exerts distinct roles in AML via ERG and cyclin D1 promoting a chemoresistant and immune-suppressive environment. Blood Adv. 2023;7:1577–93.
Google ScholarÂ
Yamazaki H, Suzuki M, Otsuki A, Shimizu R, Bresnick EH, Engel JD, et al. A remote GATA2 hematopoietic enhancer drives leukemogenesis in inv(3)(q21;q26) by activating EVI1 expression. Cancer Cell. 2014;25:415–27.
Google ScholarÂ
Smeenk L, Ottema S, Mulet-Lazaro R, Ebert A, Havermans M, Varea AA, et al. Selective requirement of MYB for oncogenic hyperactivation of a translocated enhancer in leukemia. Cancer Discov. 2021;11:2868–83.
Google ScholarÂ
Ottema S, Mulet-Lazaro R, Erpelinck-Verschueren C, van Herk S, Havermans M, Arricibita Varea A, et al. The leukemic oncogene EVI1 hijacks a MYC super-enhancer by CTCF-facilitated loops. Nat Commun. 2021;12:5679.
Google ScholarÂ
Nucifora G, Birn DJ, Espinosa R, Erickson P, LeBeau MM, Roulston D, et al. Involvement of the AML1 gene in the t(3;21) in therapy-related leukemia and in chronic myeloid leukemia in blast crisis. Blood. 1993;81:2728–34.
Google ScholarÂ
Raynaud SD, Baens M, Grosgeorge J, Rodgers K, Reid CD, Dainton M, et al. Fluorescence in situ hybridization analysis of t(3; 12)(q26; p13): a recurring chromosomal abnormality involving the TEL gene (ETV6) in myelodysplastic syndromes. Blood. 1996;88:682–9.
Google ScholarÂ
Arai S, Yoshimi A, Shimabe M, Ichikawa M, Nakagawa M, Imai Y, et al. Evi-1 is a transcriptional target of mixed-lineage leukemia oncoproteins in hematopoietic stem cells. Blood. 2011;117:6304–14.
Google ScholarÂ
Gröschel S, Lugthart S, Schlenk RF, Valk PJ, Eiwen K, Goudswaard C, et al. High EVI1 expression predicts outcome in younger adult patients with acute myeloid leukemia and is associated with distinct cytogenetic abnormalities. J Clin Oncol. 2010;28:2101–7.
Google ScholarÂ
Tang Z, Wang W, Yang S, El Achi H, Fang H, Nahmod KA. et al. 3q26.2/MECOM rearrangements by pericentric Inv(3): diagnostic challenges and clinicopathologic features. Cancers. 2023;15:458
Google ScholarÂ
Qin YZ, Zhao T, Zhu HH, Wang J, Jia JS, Lai YY, et al. High EVI1 expression predicts poor outcomes in adult acute myeloid leukemia patients with intermediate cytogenetic risk receiving chemotherapy. Med Sci Monit. 2018;24:758–67.
Google ScholarÂ
Maicas M, Vazquez I, Vicente C, Garcia-Sanchez MA, Marcotegui N, Urquiza L, et al. Functional characterization of the promoter region of the human EVI1 gene in acute myeloid leukemia: RUNX1 and ELK1 directly regulate its transcription. Oncogene. 2013;32:2069–78.
Google ScholarÂ
Manachai N, Saito Y, Nakahata S, Bahirvani AG, Osato M, Morishita K. Activation of EVI1 transcription by the LEF1/β-catenin complex with p53-alteration in myeloid blast crisis of chronic myeloid leukemia. Biochem Biophys Res Commun. 2017;482:994–1000.
Google ScholarÂ
Unoki M, Okutsu J, Nakamura Y. Identification of a novel human gene, ZFP91, involved in acute myelogenous leukemia. Int J Oncol. 2003;22:1217–23.
Google ScholarÂ
Jin X, Jin HR, Jung HS, Lee SJ, Lee JH, Lee JJ. An atypical E3 ligase zinc finger protein 91 stabilizes and activates NF-kappaB-inducing kinase via Lys63-linked ubiquitination. J Biol Chem. 2010;285:30539–47.
Google ScholarÂ
Wu W, Nelson GM, Koch R, Donovan KA, Nowak RP, Heavican-Foral TB, et al. Overcoming IMiD resistance in T-cell lymphomas through potent degradation of ZFP91 and IKZF1. Blood. 2022;139:2024–37.
Google ScholarÂ
Zhang Z, Zhong L, Dan W, Chu X, Liu C, Luo X, et al. ZFP91 promotes cell proliferation and inhibits cell apoptosis in AML via inhibiting the proteasome-dependent degradation of RIP1. Int J Med Sci. 2022;19:274–85.
Google ScholarÂ
Mi C, Wang Z, Li MY, Zhang ZH, Ma J, Jin X. Zinc finger protein 91 positively regulates the production of IL-1β in macrophages by activation of MAPKs and non-canonical caspase-8 inflammasome. Br J Pharmacol. 2018;175:4338–52.
Google ScholarÂ
Ma J, Mi C, Wang KS, Lee JJ, Jin X. Zinc finger protein 91 (ZFP91) activates HIF-1α via NF-κB/p65 to promote proliferation and tumorigenesis of colon cancer. Oncotarget. 2016;7:36551–62.
Google ScholarÂ
Sanjana NE, Shalem O, Zhang F. Improved vectors and genome-wide libraries for CRISPR screening. Nat Methods. 2014;11:783–4.
Google ScholarÂ
Joung J, Konermann S, Gootenberg JS, Abudayyeh OO, Platt RJ, Brigham MD, et al. Genome-scale CRISPR-Cas9 knockout and transcriptional activation screening. Nat Protoc. 2017;12:828–63.
Google ScholarÂ
Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A, et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol. 2002;3:RESEARCH0034.
Pfaffl MW, Tichopad A, Prgomet C, Neuvians TP. Determination of stable housekeeping genes, differentially regulated target genes and sample integrity: bestKeeper-excel-based tool using pair-wise correlations. Biotechnol Lett. 2004;26:509–15.
Google ScholarÂ
Grandi FC, Modi H, Kampman L, Corces MR. Chromatin accessibility profiling by ATAC-seq. Nat Protoc. 2022;17:1518–52.
Google ScholarÂ
Fichelson S, Dreyfus F, Berger R, Melle J, Bastard C, Miclea JM, et al. Evi-1 expression in leukemic patients with rearrangements of the 3q25-q28 chromosomal region. Leukemia. 1992;6:93–99.
Google ScholarÂ
Naumann S, Reutzel D, Speicher M, Decker HJ. Complete karyotype characterization of the K562 cell line by combined application of G-banding, multiplex-fluorescence in situ hybridization, fluorescence in situ hybridization, and comparative genomic hybridization. Leuk Res. 2001;25:313–22.
Google ScholarÂ
Mackinnon RN, Wall M, Zordan A, Nutalapati S, Mercer B, Peverall J, et al. Genome organization and the role of centromeres in evolution of the erythroleukaemia cell line HEL. Evol Med Public Health. 2013;2013:225–40.
Google ScholarÂ
Iwamoto K, Bundo M, Ueda J, Nakano Y, Ukai W, Hashimoto E, et al. Detection of chromosomal structural alterations in single cells by SNP arrays: a systematic survey of amplification bias and optimized workflow. PLoS ONE. 2007;2:e1306.
Google ScholarÂ
Zhao C, Wang Q, Wang B, Sun Q, He Z, Hong J, et al. IGF-1 induces the epithelial-mesenchymal transition via Stat5 in hepatocellular carcinoma. Oncotarget. 2017;8:111922–30.
Google ScholarÂ
Li B, Shen W, Peng H, Li Y, Chen F, Zheng L, et al. Fibronectin 1 promotes melanoma proliferation and metastasis by inhibiting apoptosis and regulating EMT. Onco Targets Ther. 2019;12:3207–21.
Google ScholarÂ
Yang L, Wang L, Yang Z, Jin H, Zou Q, Zhan Q, et al. Up-regulation of EMT-related gene VCAN by NPM1 mutant-driven TGF-β/cPML signalling promotes leukemia cell invasion. J Cancer. 2019;10:6570–83.
Google ScholarÂ
Stavropoulou V, Kaspar S, Brault L, Sanders MA, Juge S, Morettini S, et al. MLL-AF9 expression in hematopoietic stem cells drives a highly invasive AML expressing EMT-related genes linked to poor outcome. Cancer Cell. 2016;30:43–58.
Google ScholarÂ
Tang DE, Dai Y, Xu Y, Lin LW, Liu DZ, Hong XP, et al. The ubiquitinase ZFP91 promotes tumor cell survival and confers chemoresistance through FOXA1 destabilization. Carcinogenesis. 2020;41:56–66.
Google ScholarÂ
Rao SS, Huntley MH, Durand NC, Stamenova EK, Bochkov ID, Robinson JT, et al. A 3D map of the human genome at kilobase resolution reveals principles of chromatin looping. Cell. 2014;159:1665–80.
Google ScholarÂ
Wang Y, Song F, Zhang B, Zhang L, Xu J, Kuang D, et al. The 3D Genome Browser: a web-based browser for visualizing 3D genome organization and long-range chromatin interactions. Genome Biol. 2018;19:151.
Google ScholarÂ
Ng HL, Robinson ME, May PC, Innes AJ, Hiemeyer C, Feldhahn N. Promoter-centred chromatin interactions associated with EVI1 expression in EVI1+3q- myeloid leukaemia cells. Br J Haematol. 2024;204:945–58.
Google ScholarÂ
Ayoub E, Wilson MP, McGrath KE, Li AJ, Frisch BJ, Palis J, et al. EVI1 overexpression reprograms hematopoiesis via upregulation of Spi1 transcription. Nat Commun. 2018;9:4239.
Google ScholarÂ
Schmoellerl J, Barbosa IAM, Minnich M, Andersch F, Smeenk L, Havermans M. et al. EVI1 drives leukemogenesis through aberrant ERG activation. Blood. 2022;141:453–66.
Google ScholarÂ
Elster D, Tollot M, Schlegelmilch K, Ori A, Rosenwald A, Sahai E, et al. TRPS1 shapes YAP/TEAD-dependent transcription in breast cancer cells. Nat Commun. 2018;9:3115.
Google ScholarÂ
Yamamoto A, Kurata M, Onishi I, Sugita K, Matsumura M, Ishibashi S, et al. CRISPR screening identifies M1AP as a new MYC regulator with a promoter-reporter system. PeerJ. 2020;8:e9046.
Google ScholarÂ
Zhang H, Zhang Y, Zhou X, Wright S, Hyle J, Zhao L. et al. Functional interrogation of HOXA9 regulome in MLLr leukemia via reporter-based CRISPR/Cas9 screen. eLife. 2020;9:453–66.
Google ScholarÂ
Spisak S, Chen D, Likasitwatanakul P, Doan P, Li Z, Bala P, et al. Identifying regulators of aberrant stem cell and differentiation activity in colorectal cancer using a dual endogenous reporter system. Nat Commun. 2024;15:2230.
Google ScholarÂ
Hanafi M, Chen X, Neamati N. Discovery of a napabucasin PROTAC as an effective degrader of the E3 ligase ZFP91. J Med Chem. 2021;64:1626–48.
Google ScholarÂ
An J, Ponthier CM, Sack R, Seebacher J, Stadler MB, Donovan KA, et al. pSILAC mass spectrometry reveals ZFP91 as IMiD-dependent substrate of the CRL4. Nat Commun. 2017;8:15398.
Google ScholarÂ
Chen D, Wang Y, Lu R, Jiang X, Chen X, Meng N, et al. E3 ligase ZFP91 inhibits hepatocellular carcinoma metabolism reprogramming by regulating PKM splicing. Theranostics. 2020;10:8558–72.
Google ScholarÂ
Zhu Y, Zhang J, Ye Z, Peng P, Lan X, Xie L, et al. Evi-1 influence on clinical progress of colorectal cancer patients. Ann Clin Lab Sci. 2020;50:354–60.
Google ScholarÂ
Kim HR, Yim J, Yoo HB, Lee SE, Oh S, Jung S, et al. EVI1 activates tumor-promoting transcriptional enhancers in pancreatic cancer. NAR Cancer. 2021;3:zcab023.
Google ScholarÂ
Yasui K, Konishi C, Gen Y, Endo M, Dohi O, Tomie A, et al. EVI1, a target gene for amplification at 3q26, antagonizes transforming growth factor-β-mediated growth inhibition in hepatocellular carcinoma. Cancer Sci. 2015;106:929–37.
Google ScholarÂ
